Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor
- 426 Downloads
Telaprevir, a novel hepatitis C virus (HCV) NS3-4A serine protease inhibitor, has demonstrated substantial antiviral activity in patients infected with HCV. However, drug-resistant HCV variants were detected in vivo at relatively high frequency a few days after drug administration. Here we use a two-strain mathematical model to explain the rapid emergence of drug resistance in HCV patients treated with telaprevir monotherapy. We examine the effects of backward mutation and liver cell proliferation on the preexistence of the mutant virus and the competition between wild-type and drug-resistant virus during therapy. We also extend the two-strain model to a general model with multiple viral strains. Mutations during therapy only have a minor effect on the dynamics of various viral strains, although they are capable of generating low levels of HCV variants that would otherwise be completely suppressed because of fitness disadvantages. Liver cell proliferation may not affect the pretreatment frequency of mutant variants, but is able to influence the quasispecies dynamics during therapy. It is the relative fitness of each mutant strain compared with wild-type that determines which strain(s) will dominate the virus population. This study provides a theoretical framework for exploring the prevalence of preexisting mutant variants and the evolution of drug resistance during treatment with other HCV protease inhibitors or polymerase inhibitors.
KeywordsTelaprevir Mutation Fitness Quasispecies Direct-acting antiviral agents Mathematical model
- Chayama, K., Takahashi, S., Toyota, J., Karino, Y., Ikeda, K., et al. (2012). Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology, 55, 742–748. CrossRefGoogle Scholar
- Chu, H., Herrmann, E., Reesink, H., Forestier, N., Weegink, C., et al. (2005). Pharmacokinetics of VX-950, and its effect on hepatitis C viral dynamics. Hepatology, 42 Suppl 1, S694. Google Scholar
- Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., et al. (1998). Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med., 339, 1493–1499. CrossRefGoogle Scholar
- Domingo, E. (1996). Biological significance of viral quasispecies. Viral Hepat. Rev., 2, 247–261. Google Scholar
- Elahi, E., & Ronaghi, M. (2004). Pyrosequencing: A tool for DNA sequencing analysis. Methods Mol. Biol., 255, 211–219. Google Scholar
- Gillespie, J. (1998). Population genetics: a concise guide. Baltimore: Johns Hopkins University Press. Google Scholar
- Jazwinski, A. B. & Muir, A. J. (2011). Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol. Hepatol. 7, 154–162. Google Scholar
- Khunvichai, A., Chu, H., Garg, V., McHutchison, J., Lawitz, E., et al. (2007). Predicting HCV treatment duration with an HCV protease inhibitor co-administered with PEG-IFN/RBV by modeling both wild-type virus and low level resistant variant dynamics. In Digestive disease week 2007. Washington, D.C., May 19–24, 2007. Google Scholar
- McCown, M. F., Rajyaguru, S., Le Pogam, S., Ali, S., Jiang, W. R., et al. (2008). The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother., 52, 1604–1612. CrossRefGoogle Scholar
- McPhee, F., Hernandez, D., Zhai, G., Friborg, J., Yu, F., et al. (2006). Pre-existence of substitutions conferring resistance to HCV NS3 protease inhibitors. In 1st international workshop on hepatitis C resistance and new compounds. Boston, MA, October 25–26, 2006. Google Scholar
- Powers, K. A., Dixit, N. M., Ribeiro, R. M., Golia, P., Talal, A. H., et al. (2003). Modeling viral and drug kinetics: Hepatitis C virus treatment with pegylated interferon alfa-2b. Semin. Liver Dis., 23 Suppl 1, 13–18. Google Scholar
- World Health Organization (2011) Hepatitis C. Fact sheet No. 164. Revised June 2011. http://www.who.int/mediacentre/factsheets/fs164/en/index.html.